• Zhengye Biotechnology's net loss narrowed 13% year-over-year to RMB 22.16 million for the six months ended June 30, 2026.
• Net revenues fell 18% year-over-year to RMB 50.95 million.
• Net cash used in operating activities increased 20% year-over-year to RMB 16.81 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhengye Biotechnology Holding Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-118931), on November 12, 2026, and is solely responsible for the information contained therein.